****

**TABLE OF CONTENTS**

[1. REPORT OVERVIEW 16](#_Toc61009258)

[1.1 Statement of the Report 17](#_Toc61009259)

[1.2 Target Demographic 19](#_Toc61009260)

[1.3 Report Sources 19](#_Toc61009261)

[1.4 Purpose of the Report 20](#_Toc61009262)

[1.4.1 To Survey Recent MSC Advancements 20](#_Toc61009263)

[1.4.2 To Provide a “Snapshot” of Global MSC Market 20](#_Toc61009264)

[1.4.3 To Assess Opportunities for Commercialization 21](#_Toc61009265)

[1.4.4 To Identify Major Market Players and Assess the Competitive Environment 21](#_Toc61009266)

[1.4.5 To Identify Existing and Emerging Trends 21](#_Toc61009267)

[1.4.6 To Identify Critical Opportunities and Threats within the MSC Market 22](#_Toc61009268)

[1.5 Executive Summary 22](#_Toc61009269)

[1.6 Introduction 24](#_Toc61009270)

[2. MESECHYMAL STEM CELLS (MSCS): AN OVERVIEW 26](#_Toc61009271)

[2.1 The Impact of MSCs on Regenerative Medicine 26](#_Toc61009272)

[2.2 Timeline of MSC Nomenclature 27](#_Toc61009273)

[2.3 Sources of MSCs 27](#_Toc61009274)

[2.3.1 Bone Marrow-Derived MSCs (BM-MSCs) 28](#_Toc61009275)

[2.3.2 Adipose-Derived MSCs (AD-MSCs) 29](#_Toc61009276)

[2.3.3 Umbilical Cord-Derived MSCs (UC-MSCs) 29](#_Toc61009277)

[2.4 Cell Surface Markers in MSCs 30](#_Toc61009278)

[2.5 *In Vitro* Differentiation Potentials of MSCs 31](#_Toc61009279)

[2.6 Soluble Factors Secreted by MSCs 32](#_Toc61009280)

[3. MANUFACTURE OF MESENCHYMAL STEM CELLS 34](#_Toc61009281)

[3.1 Methods of Isolation of MSCs 35](#_Toc61009282)

[3.2 From Conventional Cultures to Bioreactors 36](#_Toc61009283)

[3.2.1 Monolayer Culture Systems 36](#_Toc61009284)

[3.2.2 Bioreactor-Based Cell Expansion 37](#_Toc61009285)

[3.2.3 Stirred Tank Bioreactor 37](#_Toc61009286)

[3.2.4 Rocking Bioreactor 38](#_Toc61009287)

[3.2.5 Hollow Fiber Bioreactors 38](#_Toc61009288)

[3.2.6 Fixed-Bed Bioreactors 39](#_Toc61009289)

[3.3 Main Features of Commercial Bioreactors 44](#_Toc61009290)

[3.4 Microcarriers used for the Expansion of MSCs 46](#_Toc61009291)

[3.5 Downstream Processing of MSCs 48](#_Toc61009292)

[3.5.1 Cell Detachment and Separation 48](#_Toc61009293)

[3.5.2 Cell Washing and Concentration 50](#_Toc61009294)

[3.5.3 Safety and Potency Assays 50](#_Toc61009295)

[3.5.4 Surface Markers for Identification during MSC Manufacture 50](#_Toc61009296)

[4. COMPARISON OF AUTOLOGOUS AND ALLOGENEIC MSC MANUFACTURE 52](#_Toc61009297)

[4.1 Manufacturing Cost Compared 52](#_Toc61009298)

[4.1.1 Cost Differential 53](#_Toc61009299)

[4.1.2 Cost of Donor Screening and Testing 53](#_Toc61009300)

[4.1.3 Cost for Release Testing 54](#_Toc61009301)

[4.2 Comparison of the Two Business Models 54](#_Toc61009302)

[4.2.1 Risk of Immune Reaction 54](#_Toc61009303)

[4.2.2 Risk of Cross Contamination 55](#_Toc61009304)

[4.2.3 Commercially Attractive Option 55](#_Toc61009305)

[4.3 Cost Breakdown in MSC Manufacturing 55](#_Toc61009306)

[4.4 Opportunities for Cost Reduction 57](#_Toc61009307)

[4.5 Partial Automation vs. Full Automation 58](#_Toc61009308)

[4.5.1 Partial Automation: The Most Attractive Option 60](#_Toc61009309)

[5. SMALL SCALE PROCESSING OF MSCS 61](#_Toc61009310)

[5.1 Model Design 61](#_Toc61009311)

[5.2 Culture Media 62](#_Toc61009312)

[6. LARGE-SCALE EXPANSION OF MSCS 67](#_Toc61009313)

[6.1 The Four Common Bioprocessing Strategies for Large-Scale Expansion 68](#_Toc61009314)

[6.2 Commonly Used Sources of MSCs for Large-Scale Expansion 69](#_Toc61009315)

[6.3 The Commonly Used Culture Medium for the Large-Scale Expansion of MSCs 70](#_Toc61009316)

[6.3.1 Expansion Ratio Achieved with Different Culture Media 70](#_Toc61009317)

[6.4 Comparison between Large-Scale Bioprocessing Strategies 72](#_Toc61009318)

[6.5 Contract Manufacturing for Cell Therapies 72](#_Toc61009319)

[6.5.1 Contract Manufacturing Organizations (CMOs) 73](#_Toc61009320)

[6.5.2 Contract Development and Manufacturing Organizations (CDMOs) 73](#_Toc61009321)

[6.5.2.1 Major Services Offered by CMOs 73](#_Toc61009322)

[6.5.2.2 Regional Distribution of CMOs 74](#_Toc61009323)

[6.6 Global Cell Therapy Manufacturing Capacity 75](#_Toc61009324)

[6.6.1 Major Cell Therapy CMOs/CDMOs in the U.S 76](#_Toc61009325)

[6.6.2 Major CMOs/CDMOs for Cell Therapy Manufacturing in Europe 77](#_Toc61009326)

[7. ESTIMATED CONSUMPTION OF MSCS IN THE INDUSTRY 78](#_Toc61009327)

[7.1 Consumption of MSCs in Academic and Preclinical Settings 79](#_Toc61009328)

[7.2 MSC Consumption in Clinical Settings 79](#_Toc61009329)

[7.3 Consumption of MSCs by Target Indications in Clinical Trials 80](#_Toc61009330)

[7.4 Future Consumption through 2030 81](#_Toc61009331)

[7.4.1 Consumption for MSC Therapeutics 81](#_Toc61009332)

[7.4.2 Consumption for Engineered Tissues and Organs 81](#_Toc61009333)

[7.4.3 MSC Consumption by MSC-Derived Products 82](#_Toc61009334)

[7.4.4 MSC Consumption in Emerging Industries 82](#_Toc61009335)

[7.5 Cost of MSCs per Patient used in Clinical Trials by Indication 82](#_Toc61009336)

[8. PUBLISHED SCIENTIFIC PAPERS ON MSCS 84](#_Toc61009337)

[8.1 Number of Papers on MSCs & iPSCs Compared 85](#_Toc61009338)

[8.2 Number of Papers on MSCs by Source 87](#_Toc61009339)

[8.3 Number of Papers Published on Clinical Trials Involving MSCs 88](#_Toc61009340)

[8.3.1 Number of Papers on Clinical Trials using MSCs for Specific Diseases 89](#_Toc61009341)

[9. CLINICAL TRIALS OF MSCS, MSC-BASED COVID-19, MSC-EXOSOMES 91](#_Toc61009342)

[9.1 Analysis of Data from ClinicalTrials.gov 91](#_Toc61009343)

[9.2 Sources of MSCs for Clinical Trials 92](#_Toc61009344)

[9.3 Autologous vs. Allogeneic MSCs 93](#_Toc61009345)

[9.4 Regional Distribution of MSC-Based Clinical Trials 94](#_Toc61009346)

[9.4.1 Major Countries Involved in MSC-Based Clinical Trials 95](#_Toc61009347)

[9.5 Types of Funding for MSC-Based Clinical Trials 97](#_Toc61009348)

[9.6 Types of MSC-Based Clinical Trials 98](#_Toc61009349)

[9.7 MSC-Based Clinical Trials by Phase of Development 99](#_Toc61009350)

[9.8 Clinical Trials Involving MSCs for the Treatment of COVID-19 100](#_Toc61009351)

[9.8.1 MSC-Based COVID-19 Clinical Trials by Geography 100](#_Toc61009352)

[9.9 Clinical Trials Involving MSC-Derived Exosomes 102](#_Toc61009353)

[9.10 NIH Funding for MSC Research 103](#_Toc61009354)

[9.11 CIRM’s Funding for MSC Projects 105](#_Toc61009355)

[9.11.1 CIRM Funding for MSC-Based Clinical Trials 106](#_Toc61009356)

[10. CURRENT SUB-OPTIMAL CLINICAL OUTCOMES & SOLUTIONS 107](#_Toc61009357)

[10.1 To Overcome Challenges Arising from MSC Manufacture 107](#_Toc61009358)

[10.1.1 Heterogeneity in the MSC Product 107](#_Toc61009359)

[10.2 Cryopreservation and Culture Rescue 109](#_Toc61009360)

[10.2.1 Bioengineering Solutions to Boost MSC Function 109](#_Toc61009361)

[10.2.2 Engineering MSCs to Carry Anti-Cancer “Trogan Horses” 111](#_Toc61009362)

[10.3 Overcoming Clinical Challenges Related to Infusion 112](#_Toc61009363)

[10.3.1 Local Administration 112](#_Toc61009364)

[10.3.2 Insufficient Retention and Survival 112](#_Toc61009365)

[10.3.3 Strategies to Improve Local Administration 112](#_Toc61009366)

[10.4 To Overcome Clinical Challenges from the Host 113](#_Toc61009367)

[11. MODIFICATION OF MSCS 115](#_Toc61009368)

[11.1 Genetic Modification 116](#_Toc61009369)

[11.1.1 Gene Modification to Improve Migration 116](#_Toc61009370)

[11.1.2 Gene Modification to Improve Adhesion 116](#_Toc61009371)

[11.1.3 Genetic Modification to Improve Survival 116](#_Toc61009372)

[11.1.4 Genetic Modification to Reduce Premature Senescence 117](#_Toc61009373)

[11.2 Preconditioning Modifications 117](#_Toc61009374)

[11.2.1 Preconditioning to Improve Migration 117](#_Toc61009375)

[11.2.2 Preconditioning to Improve Adhesion 118](#_Toc61009376)

[11.2.3 Preconditioning to Improve Survival 118](#_Toc61009377)

[11.2.4 Preconditioning to Reduce Senescence 118](#_Toc61009378)

[11.3 Therapeutic Application of Modified MSCs 118](#_Toc61009379)

[11.3.1 Modified MSCs for Neurological Conditions 119](#_Toc61009380)

[11.3.2 Modified MSCs for Cardiovascular Diseases 120](#_Toc61009381)

[11.3.3 Modified MSCs for Lung Injury 120](#_Toc61009382)

[11.3.4 Modified MSCs for Diabetes 121](#_Toc61009383)

[12. MAJOR DISEASES ADDRESSED BY MSCS IN CLINICAL TRIALS 122](#_Toc61009384)

[12.1 Clinical Trials using MSCs for Autoimmune Diseases 122](#_Toc61009385)

[12.2 Clinical Trials using MSCs for Cardiovascular Diseases 123](#_Toc61009386)

[12.3 Clinical Trials using MSCs for Neurodegenerative Diseases 124](#_Toc61009387)

[12.4 Clinical Trials using MSCs for Bone and Cartilage Diseases 125](#_Toc61009388)

[13. PRESENT STATUS OF MESENCHYMAL STEM CELL INDUSTRY 127](#_Toc61009389)

[13.1 Sources of MSCs for Research and Clinical Applications 127](#_Toc61009390)

[13.2 Allogeneic Products Gaining Traction 128](#_Toc61009391)

[13.3 MSC-Based Products with Marketing Approval 129](#_Toc61009392)

[13.3.1 Alofisel 131](#_Toc61009393)

[13.3.2 Stemirac 132](#_Toc61009394)

[13.3.3 Stempeucel 132](#_Toc61009395)

[13.3.4 Temcell HS 132](#_Toc61009396)

[13.3.5 Neuronata-R 133](#_Toc61009397)

[13.3.6 Prochymal (Remestemcel-L) 133](#_Toc61009398)

[13.3.7 Cupistem 133](#_Toc61009399)

[13.3.8 Cartistem 133](#_Toc61009400)

[13.3.9 Cellgram-AMI 134](#_Toc61009401)

[13.3.10 Queencell 134](#_Toc61009402)

[13.4 Currently Marketed MSC-Based Bone Matrices 134](#_Toc61009403)

[13.4.1 Osteocel 135](#_Toc61009404)

[13.4.2 AlloStem 136](#_Toc61009405)

[13.4.3 Cellentra VCBM 136](#_Toc61009406)

[13.4.4 HiQCell 137](#_Toc61009407)

[13.4.5 Trinity ELITE 137](#_Toc61009408)

[13.4.6 Map3 137](#_Toc61009409)

[13.4.7 Trinity Evolution 137](#_Toc61009410)

[13.4.8 Carticel 138](#_Toc61009411)

[13.4.9 Chondron 138](#_Toc61009412)

[13.4.10 DeNovo NT 138](#_Toc61009413)

[13.4.11 Chondrocelect 138](#_Toc61009414)

[13.4.12 Ossron 139](#_Toc61009415)

[13.4.13 JACC 139](#_Toc61009416)

[13.4.14 MACI 139](#_Toc61009417)

[13.4.15 Ortho-ACI 140](#_Toc61009418)

[13.4.16 Spherox 140](#_Toc61009419)

[13.4.17 Ossgrow 140](#_Toc61009420)

[13.4.18 Cartigrow 141](#_Toc61009421)

[13.4.19 ViviGen 141](#_Toc61009422)

[13.4.20 Bio4 141](#_Toc61009423)

[13.4.21 Cartiform 141](#_Toc61009424)

[13.5 From Whole Cell MSC Therapy to MSC-Derived Exosome Therapy 142](#_Toc61009425)

[13.5.1 Advantages of MSC-Derived Exosomes 142](#_Toc61009426)

[13.5.2 Contents of MSC-Derived Exosomes 142](#_Toc61009427)

[13.5.3 Exosomes as Diagnostics 143](#_Toc61009428)

[13.5.4 Exosomes as Drug Delivery Vectors 143](#_Toc61009429)

[13.6 MSC-Based Therapy for COVID-19 143](#_Toc61009430)

[13.7 MSC-Based Clean Meat Production 144](#_Toc61009431)

[13.8 Stem Cell-Based Cosmetics 144](#_Toc61009432)

[13.8.1 Marketed Stem Cell-Based Cosmetic Products 145](#_Toc61009433)

[14. MARKET ANALYSIS 153](#_Toc61009434)

[14.1 Price Tags for MSC-Based Cell Therapy (CT) Treatment 154](#_Toc61009435)

[14.2 Price Tags for MSC-Based Matrices 155](#_Toc61009436)

[14.3 Market Size of MSC-Based Therapies 156](#_Toc61009437)

[14.4 Global Market for MSC-based Therapeutics 157](#_Toc61009438)

[14.5 Global Demand for Mesenchymal Stem Cells (MSCs) 159](#_Toc61009439)

[14.5.1 MSCs Required for Academic and Preclinical Research 159](#_Toc61009440)

[14.5.2 Required MSCs for Clinical Trials 159](#_Toc61009441)

[14.5.3 MSCs Required for Developing MSC-Based Therapeutics 159](#_Toc61009442)

[14.5.4 MSCs Required for Developing MSC-Derived Products 160](#_Toc61009443)

[14.5.5 MSCs Required for Emerging Industries 160](#_Toc61009444)

[14.5.6 Global Market Size for Mesenchymal Stem Cells 160](#_Toc61009445)

[14.6 Market Share of MSC-Based Business Segments 162](#_Toc61009446)

[15. COMPANY PROFILES 164](#_Toc61009447)

[15.1 101 Bio 164](#_Toc61009448)

[15.1.1 Exosome Services 164](#_Toc61009449)

[15.2 Adipomics, Inc. 165](#_Toc61009450)

[15.3 Aegle Therapeutics 165](#_Toc61009451)

[15.3.1 Aegle’s Platform Technology 166](#_Toc61009452)

[15.3.1.1 Epidermolysis Bullosa 166](#_Toc61009453)

[15.4 Aethlon Medical, Inc. 166](#_Toc61009454)

[15.4.1 Hemopurifier in Cancer 167](#_Toc61009455)

[15.5 AgeX Therapeutics, Inc. 167](#_Toc61009456)

[15.5.1 PureStem Technology 167](#_Toc61009457)

[15.5.2 Induced Tissue Regeneration (iTR) 168](#_Toc61009458)

[15.5.3 UniverCyte 168](#_Toc61009459)

[15.6 Alexerion Biotech Corp. 169](#_Toc61009460)

[15.6.1 Drug Development 169](#_Toc61009461)

[15.7 AlloSource, Inc. 170](#_Toc61009462)

[15.7.1 Products 170](#_Toc61009463)

[15.7.1.1 AlloStem 170](#_Toc61009464)

[15.8 American CryoStem Corporation 171](#_Toc61009465)

[15.8.1 Services 171](#_Toc61009466)

[15.8.1.1 ATGRAFT Fat Storage 171](#_Toc61009467)

[15.8.1.2 Adult Stem Cell Program 171](#_Toc61009468)

[15.8.2 Products 171](#_Toc61009469)

[15.8.2.1 CELECT Tissue Harvesting System 171](#_Toc61009470)

[15.8.2.2 ATCELL-AD-MSCs 172](#_Toc61009471)

[15.8.2.3 ACSelerateMAX Growth Medium 172](#_Toc61009472)

[15.9 American Type Culture Collection (ATCC) 173](#_Toc61009473)

[15.9.1 Stem Cell Products 173](#_Toc61009474)

[15.10 AMS Biotechnology, Ltd. (AMSBIO) 174](#_Toc61009475)

[15.10.1 Products 174](#_Toc61009476)

[15.11 Anemocyte S.r.l 175](#_Toc61009477)

[15.11.1 Total GMP Capacity 175](#_Toc61009478)

[15.11.2 Product Types 175](#_Toc61009479)

[15.11.3 Manufacturing Services 175](#_Toc61009480)

[15.12 Anjarium Biosciences 176](#_Toc61009481)

[15.12.1 Anjarium’s Hybridosome Platform 176](#_Toc61009482)

[15.13 Anterogen, Co., Ltd. 177](#_Toc61009483)

[15.13.1 Products 177](#_Toc61009484)

[15.13.1.1 Cupistem Injection 177](#_Toc61009485)

[15.13.1.2 Queencell Injection 177](#_Toc61009486)

[15.14 Apceth Biopharma GmbH 178](#_Toc61009487)

[15.14.1 Global Services 178](#_Toc61009488)

[15.14.2 Assay Development Services 179](#_Toc61009489)

[15.15 Aruna Bio 180](#_Toc61009490)

[15.15.1 AB126 180](#_Toc61009491)

[15.16 Athersys, Inc. 181](#_Toc61009492)

[15.16.1 MultiStem 181](#_Toc61009493)

[15.17 Avalon GloboCare Corp. 182](#_Toc61009494)

[15.17.1 Avalon’s Core Platforms 182](#_Toc61009495)

[15.18 Axol Bioscience, Ltd. 183](#_Toc61009496)

[15.18.1 Products 183](#_Toc61009497)

[15.19 Azymus Therapeutics 184](#_Toc61009498)

[15.19.1 AZ Platform 184](#_Toc61009499)

[15.20 BioCat GmbH 185](#_Toc61009500)

[15.20.1 Exosome Purification Kits 185](#_Toc61009501)

[15.21 BioFluidica 186](#_Toc61009502)

[15.21.1 Technology Platform 186](#_Toc61009503)

[15.22 Bio-Techne 187](#_Toc61009504)

[15.22.1 Total GMP Capacity 187](#_Toc61009505)

[15.22.2 Prtoduct Types 187](#_Toc61009506)

[15.23 BioVision, Inc. 188](#_Toc61009507)

[15.24 Baylx, Inc. 189](#_Toc61009508)

[15.24.1 Product Candidates 189](#_Toc61009509)

[15.25 BrainStorm Cell Therapeutics 190](#_Toc61009510)

[15.25.1 MSC-NTF Cells 190](#_Toc61009511)

[15.26 Capricor Therapeutics 191](#_Toc61009512)

[15.26.1 Exosome Program 191](#_Toc61009513)

[15.27 Catalent Pharma Solutions 192](#_Toc61009514)

[15.27.1 Cell Therapy Expertise 192](#_Toc61009515)

[15.28 CCRM 193](#_Toc61009516)

[15.28.1 Total GMP Capacity 193](#_Toc61009517)

[15.28.2 Product Types 193](#_Toc61009518)

[15.28.3 Manufacturing Services 193](#_Toc61009519)

[15.29 CellResearch Corporation, Pte Ltd. 194](#_Toc61009520)

[15.29.1 Umbilical Cord Lining Stem Cells 194](#_Toc61009521)

[15.30 Celltex Therapeutics Corporation 195](#_Toc61009522)

[15.30.1 Therapy Services 195](#_Toc61009523)

[15.31 Ciloa 196](#_Toc61009524)

[15.31.1 Exosome Customization Technology 196](#_Toc61009525)

[15.32 Codiak Biosciences 197](#_Toc61009526)

[15.32.1 engEx Platform 197](#_Toc61009527)

[15.32.2 exoASO-STAT6 197](#_Toc61009528)

[15.32.3 exoIL-12 197](#_Toc61009529)

[15.33 Corestem, Inc. 198](#_Toc61009530)

[15.33.1 Neuronata-R 198](#_Toc61009531)

[15.34 CO-DON AG 199](#_Toc61009532)

[15.34.1 M-ACT 199](#_Toc61009533)

[15.35 Cognate BioServices, Inc. 200](#_Toc61009534)

[15.35.1 Total GMP Capacity 200](#_Toc61009535)

[15.35.2 Product Types 200](#_Toc61009536)

[15.36 Creative Bioarray 201](#_Toc61009537)

[15.37 Creative Biolabs 201](#_Toc61009538)

[15.37.1 Products 202](#_Toc61009539)

[15.37.2 Services 202](#_Toc61009540)

[15.38 Cynata Therapeutics, Ltd. 203](#_Toc61009541)

[15.38.1 Cymerus Platform 203](#_Toc61009542)

[15.38.2 GvHD 203](#_Toc61009543)

[15.38.3 Critical Limb Ischemia 204](#_Toc61009544)

[15.38.4 Asthma 204](#_Toc61009545)

[15.38.5 Heart Attack 204](#_Toc61009546)

[15.38.6 Diabetic Wounds 204](#_Toc61009547)

[15.38.7 Coronary Artery Disease (CAD) 205](#_Toc61009548)

[15.38.8 Acute Respiratory Distress Syndrome (ARDS) 205](#_Toc61009549)

[15.38.9 Sepsis 205](#_Toc61009550)

[15.38.10 Osteoarthritis 205](#_Toc61009551)

[15.39 DePuy Synthes 206](#_Toc61009552)

[15.39.1 ViviGen 206](#_Toc61009553)

[15.40 Direct Biologics 207](#_Toc61009554)

[15.40.1 ExoFlo 207](#_Toc61009555)

[15.41 EVerZom 208](#_Toc61009556)

[15.41.1 Services 208](#_Toc61009557)

[15.42 Evox Therapeutics, Ltd. 209](#_Toc61009558)

[15.42.1 Protein Therapeutics – REPLACE 209](#_Toc61009559)

[15.42.2 RNA Therapeutics – CORRECT 209](#_Toc61009560)

[15.43 Exerkine Corp. 210](#_Toc61009561)

[15.43.1 Clinical Development 210](#_Toc61009562)

[15.43.1.1 Genetic Diseases 210](#_Toc61009563)

[15.43.1.2 Aging-Associated Diseases 210](#_Toc61009564)

[15.44 ExoCan Healthcare Technologies, Pvt. Ltd. 211](#_Toc61009565)

[15.44.1 Technology 211](#_Toc61009566)

[15.44.1.1 ExoEnrich Exosome Isolation Kit 211](#_Toc61009567)

[15.44.1.2 ExoEngineering 211](#_Toc61009568)

[15.45 ExoCoBio, Co., Ltd. 212](#_Toc61009569)

[15.45.1 Products 212](#_Toc61009570)

[15.46 Exogenus Therapeutics 213](#_Toc61009571)

[15.47 EXoPERT 214](#_Toc61009572)

[15.47.1 EXo-i 214](#_Toc61009573)

[15.48 Exopharm 215](#_Toc61009574)

[15.48.1 LEAP Technology 215](#_Toc61009575)

[15.48.2 Cevaris & Plexaris 215](#_Toc61009576)

[15.49 Exosome Diagnostics, Inc. 216](#_Toc61009577)

[15.49.1 ExoDx Prostate Test 216](#_Toc61009578)

[15.50 ExosomePlus 217](#_Toc61009579)

[15.51 Exosome Sciences 218](#_Toc61009580)

[15.51.1 TauSome Biomarker 218](#_Toc61009581)

[15.52 Exosomics S.p.A 219](#_Toc61009582)

[15.52.1 ExoRef 219](#_Toc61009583)

[15.52.2 SeleCTEV Enrichment Kits 219](#_Toc61009584)

[15.52.3 SoRTEV Enrichment Kit 219](#_Toc61009585)

[15.53 Fraunhofer Institute for Cell Therapy and Immunology 220](#_Toc61009586)

[15.53.1 Total GMP Capacity 220](#_Toc61009587)

[15.53.2 Product Types 220](#_Toc61009588)

[15.53.3 Manufacturing Services 220](#_Toc61009589)

[15.54 HansaBioMed Life Sciences, Ltd. 221](#_Toc61009590)

[15.54.1 Products 221](#_Toc61009591)

[15.55 Hope Biosciences, LLC 222](#_Toc61009592)

[15.55.1 Hope’s Cell Culture Process 222](#_Toc61009593)

[15.56 Japan Tissue Engineering, Co., Ltd. 223](#_Toc61009594)

[15.56.1 JACC 223](#_Toc61009595)

[15.57 JCR Pharmaceuticals, Co., Ltd. 224](#_Toc61009596)

[15.57.1 TEMCELL HS Inj. 224](#_Toc61009597)

[15.58 Kimera Labs, Inc. 224](#_Toc61009598)

[15.59 Lonza Group Ltd. 225](#_Toc61009599)

[15.59.1 Total GMP Capacity 225](#_Toc61009600)

[15.59.2 Product Types 225](#_Toc61009601)

[15.59.3 Manufacturing Services 225](#_Toc61009602)

[15.60 Mantra Bio 226](#_Toc61009603)

[15.60.1 Partnering 226](#_Toc61009604)

[15.61 Medipost, Co., Ltd. 227](#_Toc61009605)

[15.61.1 Cartistem 227](#_Toc61009606)

[15.62 MDimune 228](#_Toc61009607)

[15.62.1 BioDrone Technology 228](#_Toc61009608)

[15.63 NanoSomix, Inc. 229](#_Toc61009609)

[15.63.1 Technology 229](#_Toc61009610)

[15.64 NanoView Biosciences 230](#_Toc61009611)

[15.64.1 Products 230](#_Toc61009612)

[15.64.1.1 ExoView R 100 230](#_Toc61009613)

[15.64.1.2 ExoView Tetraspanin Kits 230](#_Toc61009614)

[15.65 NeurExo Sciences 231](#_Toc61009615)

[15.66 Nipro Corporation 232](#_Toc61009616)

[15.66.1 Stemirac 232](#_Toc61009617)

[15.67 Novus Biologicals, LLC 233](#_Toc61009618)

[15.67.1 Exosomes Research Tools 233](#_Toc61009619)

[15.68 NuVasive, Inc. 234](#_Toc61009620)

[15.68.1 Osteocel Family 234](#_Toc61009621)

[15.69 OmniSpirant Limited 235](#_Toc61009622)

[15.69.1 Technology 235](#_Toc61009623)

[15.70 Orthocell, Ltd. 236](#_Toc61009624)

[15.70.1 Ortho-ATI 236](#_Toc61009625)

[15.70.2 CelGro 236](#_Toc61009626)

[15.71 Orthofix Medical, Inc. 237](#_Toc61009627)

[15.71.1 Trinity ELITE 237](#_Toc61009628)

[15.71.2 Trinity EVOLUTION 237](#_Toc61009629)

[15.72 Osiris Therapeutics, Inc. 238](#_Toc61009630)

[15.72.1 Cartiform 238](#_Toc61009631)

[15.72.2 Bio4 238](#_Toc61009632)

[15.73 Pharmicell, Co., Ltd. 239](#_Toc61009633)

[15.73.1 Cellgram-AMI 239](#_Toc61009634)

[15.73.2 Stem Cell Culture Media Cosmetics 240](#_Toc61009635)

[15.74 Pluristem Therapeutics, Inc. 241](#_Toc61009636)

[15.74.1 Products 241](#_Toc61009637)

[15.74.2 PLX-PAD 241](#_Toc61009638)

[15.74.3 PLX-R18 242](#_Toc61009639)

[15.74.4 PLX-Immune 242](#_Toc61009640)

[15.74.5 Partnerships and Collaborations 243](#_Toc61009641)

[15.74.5.1 Collaboration with NASA 243](#_Toc61009642)

[15.74.5.2 Collaboration with NIAID 243](#_Toc61009643)

[15.74.5.3 Collaboration with U.S. Department of Defence (DOD) 243](#_Toc61009644)

[15.74.5.4 License Agreement with Chart Industries, Inc. 243](#_Toc61009645)

[15.74.5.5 Collaboration with Thermo Fisher Scientific 244](#_Toc61009646)

[15.74.5.6 Partnership with Cha Biotech 244](#_Toc61009647)

[15.75 Regeneus, Ltd. 245](#_Toc61009648)

[15.75.1 HiQCell 245](#_Toc61009649)

[15.76 Regrow Biosciences, Pvt., Ltd. 246](#_Toc61009650)

[15.76.1 Ossgrow 246](#_Toc61009651)

[15.76.2 Cartigrow 246](#_Toc61009652)

[15.77 ReNeuron 247](#_Toc61009653)

[15.77.1 Exosome Platform 247](#_Toc61009654)

[15.78 RoosterBio 248](#_Toc61009655)

[15.78.1 Products 248](#_Toc61009656)

[15.78.2 Services 249](#_Toc61009657)

[15.79 RoslinCT 250](#_Toc61009658)

[15.79.1 Total GMP Capacity 250](#_Toc61009659)

[15.79.2 Product Types 250](#_Toc61009660)

[15.79.3 Manufacturing Services 250](#_Toc61009661)

[15.80 RTI Surgical, Inc. 251](#_Toc61009662)

[15.80.1 Map3 Allograft Chips 251](#_Toc61009663)

[15.81 Sentien Biotechnologies, Inc. 252](#_Toc61009664)

[15.81.1 SBI-101 252](#_Toc61009665)

[15.81.2 Pipeline 253](#_Toc61009666)

[15.82 STEMCELL Technologies, Inc. 254](#_Toc61009667)

[15.82.1 Products 254](#_Toc61009668)

[15.83 Stemedica Cell Technologies, Inc. 255](#_Toc61009669)

[15.83.1 BioSmart Technology 255](#_Toc61009670)

[15.83.2 Pipeline 255](#_Toc61009671)

[15.84 Stemmatters Biotechnologia e Medicina Regenerative SA 256](#_Toc61009672)

[15.85 Stempeutics Research, Pvt., Ltd. 257](#_Toc61009673)

[15.85.1 Stempeucel 257](#_Toc61009674)

[15.85.2 Stempeutron 257](#_Toc61009675)

[15.85.3 Stempeucare (Cutisera) 258](#_Toc61009676)

[15.86 System Biosciences, LLC 259](#_Toc61009677)

[15.86.1 Products 259](#_Toc61009678)

[15.86.2 Services 259](#_Toc61009679)

[15.87 Takeda Pharmaceuticals U.S.A., Inc. 260](#_Toc61009680)

[15.87.1 Alofisel 260](#_Toc61009681)

[15.88 Tempo Bioscience 261](#_Toc61009682)

[15.88.1 Products 261](#_Toc61009683)

[15.88.1.1 Human Cell Models 261](#_Toc61009684)

[15.88.1.2 Services & Alliances 262](#_Toc61009685)

[15.89 Tavec Pharma 263](#_Toc61009686)

[15.89.1 Technology 263](#_Toc61009687)

[15.90 United Therapeutics Corp. 264](#_Toc61009688)

[15.90.1 Unexisome 264](#_Toc61009689)

[15.91 Vericel Corporation 265](#_Toc61009690)

[15.91.1 MACI 265](#_Toc61009691)

[15.91.2 Carticel 265](#_Toc61009692)

[15.92 Versatope Therapeutics 266](#_Toc61009693)

[15.92.1 VT-105 266](#_Toc61009694)

[15.93 Vesigen Therapeutics, Inc. 267](#_Toc61009695)

[15.93.1 Technology 267](#_Toc61009696)

[15.94 Waisman Biomanufacturing 268](#_Toc61009697)

[15.94.1 Total GMP Capacity 268](#_Toc61009698)

[15.94.2 Product Types 268](#_Toc61009699)

[15.94.3 Manufacturing Services 268](#_Toc61009700)

[15.95 WuXi Advanced Therapies 269](#_Toc61009701)

[15.95.1 Total GMP Capacity 269](#_Toc61009702)

[15.95.2 Product Types 269](#_Toc61009703)

[15.96 XOStem, Inc. 270](#_Toc61009704)

[15.97 Zen-Bio, Inc. 271](#_Toc61009705)

[15.97.1 Products 271](#_Toc61009706)

[15.97.1.1 Human Exosomes 272](#_Toc61009707)

[15.97.2 Contract Services 273](#_Toc61009708)

[15.98 Zimmer Biomet 274](#_Toc61009709)

[15.98.1 Cellentra 274](#_Toc61009710)

**INDEX OF FIGURES**

[FIGURE 3.1: Monolayer Culture Systems 36](#_Toc61011996)

[FIGURE 3.2: Stirred Tank Bioreactor 37](#_Toc61011997)

[FIGURE 3.3: Rocking Bioreactor 38](#_Toc61011998)

[FIGURE 3.4: Hollow Fiber Bioreactors 39](#_Toc61011999)

[FIGURE 3.5: Fixed-Bed Bioreactors 39](#_Toc61012000)

[FIGURE 3.6: Single-Use Harvestainer for Small Scale Application 49](#_Toc61012001)

[FIGURE 3.7: Single-Use Harvestainer for Large Scale Application 49](#_Toc61012002)

[FIGURE 4.1: CoG in MSC Manufacturing 56](#_Toc61012003)

[FIGURE 4.2: Impact of Head Count on Overall CoG per Batch 57](#_Toc61012004)

[FIGURE 4.3: CoG Breakdown in Partially-Automated MSC Manufacturing 58](#_Toc61012005)

[FIGURE 4.4: Cost Breakdown in Fully Automated MSC Manufacturing 59](#_Toc61012006)

[FIGURE 4.5: Higher Throughput in Partially Automated Facilities 60](#_Toc61012007)

[FIGURE 5.1: Diagrammatic Representation of SelecT Automated Platform by Sartorius 65](#_Toc61012008)

[FIGURE 5.2: Model of a Clean Room in a Small-Scale Manufacturing Facility 66](#_Toc61012009)

[FIGURE 6.1: The Four Common Bioprocessing Strategies 69](#_Toc61012010)

[FIGURE 6.2: Large-Scale Expansion of MSCs by Source 69](#_Toc61012011)

[FIGURE 6.3: Commonly used Culture Media in the Large-Scale Expansion of MSCs 70](#_Toc61012012)

[FIGURE 6.4: Major Services Offered by CMOs 74](#_Toc61012013)

[FIGURE 6.5: Regional Distribution of CMOs 75](#_Toc61012014)

[FIGURE 7.1: Share of Published Papers by Type 78](#_Toc61012015)

[FIGURE 7.2: Consumption of MSCs in Academic and Preclinical Settings 79](#_Toc61012016)

[FIGURE 7.3: MSC Consumption in Clinical Settings 80](#_Toc61012017)

[FIGURE 7.4: Consumption of MSCs by Target Indications in Clinical Trials 80](#_Toc61012018)

[FIGURE 8.1: Number of Published Papers on MSCs between 2010 and 2020 85](#_Toc61012019)

[FIGURE 8.2: Number of Published Papers for MSCs and iPSCs Compared, 2010-2020 86](#_Toc61012020)

[FIGURE 8.3: Number of Papers on MSCs by Source 88](#_Toc61012021)

[FIGURE 8.4: Number of Papers on Clinical Trials Involving MSCs, 2010-2019 89](#_Toc61012022)

[FIGURE 8.5: Percent Share of Specific Diseases in Clinical Trials 90](#_Toc61012023)

[FIGURE 9.1: Distribution of Clinical Trials involving MSCs across the World, 2020 92](#_Toc61012024)

[FIGURE 9.2: Clinical Trials Involving MSCs by Source 93](#_Toc61012025)

[FIGURE 9.3: Clinical Trials Involving Autologous and Allogeneic MSCs 94](#_Toc61012026)

[FIGURE 9.4: Distribution of MSC-Based Clinical Trials by Geography, 2020 95](#_Toc61012027)

[FIGURE 9.5: Type of Funding for MSC-Based Clinical Trials 97](#_Toc61012028)

[FIGURE 9.6: The Three Types of Ongoing MSC-Based Clinical Trials, 2020 98](#_Toc61012029)

[FIGURE 9.7: MSC-Based Clinical Trials by Phase of Development, 2020 99](#_Toc61012030)

[FIGURE 9.8: MSC-Based COVID-19 Clinical Trials by Geography 100](#_Toc61012031)

[FIGURE 10.1: Bioengineering Solutions to Boost the Function of MSC 109](#_Toc61012032)

[FIGURE 10.2: Bioengineering Solutions for Improving Administration of MSCs 113](#_Toc61012033)

[FIGURE 10.3: Solutions to Overcome Host Factors 114](#_Toc61012034)

[FIGURE 11.1: Four Focal Points of Enhancement of MSC’s Properties during Modification 115](#_Toc61012035)

[FIGURE 11.2: The Cycle of Naïve MSCs to Modified MSCs for Clinical Application 119](#_Toc61012036)

[FIGURE 12.1: Major Diseases Addressed by MSCs in Clinical Trials 122](#_Toc61012037)

[FIGURE 12.2: Percent Share of Autoimmune Diseases in Clinical Trials using MSCs 123](#_Toc61012038)

[FIGURE 12.3: Percent Share of MSC by Source in Trials for Cardiovascular Diseases 124](#_Toc61012039)

[FIGURE 12.4: Percent Shares of Neurodenerative Diseases in Clinical Trials using MSCs 125](#_Toc61012040)

[FIGURE 12.5: Percent Share of MSC by Source in Trials for Bone & Cartilage Diseases 126](#_Toc61012041)

[FIGURE 14.1: Percent Share of Marketed CT, GT and TE Products 153](#_Toc61012042)

[FIGURE 14.2: Percent Share of CT Products by Indication 154](#_Toc61012043)

[FIGURE 14.3: Market for MSC-Based Cell Therapy Products by Geography, 2020-2027 158](#_Toc61012044)

[FIGURE 14.4: Global Market for Mesenchymal Stem Cells by Geography, 2020-2027 161](#_Toc61012045)

[FIGURE 14.5: Market Share of MSCc by Business Segments 163](#_Toc61012046)

# INDEX OF TABLES

[TABLE 2.1: Timeline of MSC Nomeclature 27](#_Toc61012430)

[TABLE 2.2: Sources of MSCs 28](#_Toc61012431)

[TABLE 2.3: Advantages and Disadvantages of BM-MSCs 29](#_Toc61012432)

[TABLE 2.4: Advantages and Disadvantages of AD-MSCs 29](#_Toc61012433)

[TABLE 2.5: Advantages and Disadvantages of UC-MSCs 30](#_Toc61012434)

[TABLE 2.6: Positive and Negative Markers for MSCs Derived from Different Sources 30](#_Toc61012435)

[TABLE 2.7: In Vitro Differentiation Potentials of MSCs 31](#_Toc61012436)

[TABLE 2.8: Soluble Factors Secreted by MSCs 32](#_Toc61012437)

[TABLE 3.1: Initial Story of MSCs: A Snapshot 34](#_Toc61012438)

[TABLE 3.2: Methods of Isolation of MSCs and Corresponding Culture Media 35](#_Toc61012439)

[TABLE 3.3: A Snapshot of Commercially Available Culture Systems 40](#_Toc61012440)

[TABLE 3.3: (CONTINUED) 41](#_Toc61012441)

[TABLE 3.3: (CONTINUED) 42](#_Toc61012442)

[TABLE 3.3: (CONTINUED) 43](#_Toc61012443)

[TABLE 3.3: (CONTINUED) 44](#_Toc61012444)

[TABLE 3.4: Main Features of Commercally Available Bioreactors 45](#_Toc61012445)

[TABLE 3.5: Microcarriers used for the Expansion of MSCs 46](#_Toc61012446)

[TABLE 3.5: (CONTINUED) 47](#_Toc61012447)

[TABLE 3.5: (CONTINUED) 48](#_Toc61012448)

[TABLE 3.6: Basic Assays for MSCs 50](#_Toc61012449)

[TABLE 3.7: Cell Surface Markers on MSCs and Fibroblasts 51](#_Toc61012450)

[TABLE 4.1: Cost of Manufacturing Allogeneic MSCs 52](#_Toc61012451)

[TABLE 4.2: Cost of Manufacturing Autologous MSCs 53](#_Toc61012452)

[TABLE 4.3: Comparison of Allogeneic and Autologous Therapies 55](#_Toc61012453)

[TABLE 4.4: Cost of Goods (CoG) in MSC Manufacturing 56](#_Toc61012454)

[TABLE 4.5: CoG Breakdown in Partially-Automated MSC Manufacturing 58](#_Toc61012455)

[TABLE 4.6: Cost Breakdown in Fully Automated MSC Manufacturing 59](#_Toc61012456)

[TABLE 4.7: Higher Throughput in Partially Automated Facilities 60](#_Toc61012457)

[TABLE 5.1: Key Process and Cost Assumptions 62](#_Toc61012458)

[TABLE 5.2: Quality Control Panel with Cost Assessments 63](#_Toc61012459)

[TABLE 5.3: Additional Supporting Labor Cost Assumptions 63](#_Toc61012460)

[TABLE 5.3: (CONTINUED) 64](#_Toc61012461)

[TABLE 5.4: Additional Supporting Facility and Process Assumptions 64](#_Toc61012462)

[TABLE 5.4: (CONTINUED) 65](#_Toc61012463)

[TABLE 6.1: Large-Scale Expansion of MSCs by Method, Cell Source and Media 67](#_Toc61012464)

[TABLE 6.1: (CONTINUED) 68](#_Toc61012465)

[TABLE 6.2: Expansion Ratio Achieved with Different Culture Media 71](#_Toc61012466)

[TABLE 6.3: Comparison between Large-Scale Bioprocessing Strategies 72](#_Toc61012467)

[TABLE 6.4: Regional Distribution of CMOs 74](#_Toc61012468)

[TABLE 6.5: Global Cell Therapy Manufacturing Capacity 76](#_Toc61012469)

[TABLE 6.6: Major CDMOs and CMOs in North America 76](#_Toc61012470)

[TABLE 6.7: Major CDMOs and CMOs in Europe 77](#_Toc61012471)

[TABLE 7.1: Cost of MSCs per Patient in Clinical Trials by Indication 83](#_Toc61012472)

[TABLE 8.1: Number of Published Papers on MSCs between 2010 and 2020 84](#_Toc61012473)

[TABLE 8.2: Number of Papers on MSCs & iPSCs Compared between 2010 and 2020 86](#_Toc61012474)

[TABLE 8.3: Number of Papers on MSCs by Source 87](#_Toc61012475)

[TABLE 8.4: Number of Papers on Clinical Trials Involving MSCs, 2010-2020 88](#_Toc61012476)

[TABLE 8.5: Number of Papers on Trials using MSCs for Specific Diseases, 2010-2020 90](#_Toc61012477)

[TABLE 9.1: Number of Clinical Trials Involving MSCs by Region as of Apr. 2020 91](#_Toc61012478)

[TABLE 9.2: Clinical Trials Involving MSCs by Source 93](#_Toc61012479)

[TABLE 9.3: Clinical Trials Involving Autologous vs. Allogeneic MSCs 94](#_Toc61012480)

[TABLE 9.4: Distribution of MSC-Based Clinical Trials by Geography, 2020 95](#_Toc61012481)

[TABLE 9.5: Number of MSC-Based Clinical Trials by Country as of 2020 96](#_Toc61012482)

[TABLE 9.6: Type of Funding for MSC-Based Clinical Trials, 2020 97](#_Toc61012483)

[TABLE 9.7: The Three Types of Ongoing MSC-Based Clinical Trials, 2020 98](#_Toc61012484)

[TABLE 9.8: MSC-Based Clinical Trials by Phase of Development, 2020 99](#_Toc61012485)

[TABLE 9.9: Number of COVID-19 Clinical Trials by Country 101](#_Toc61012486)

[TABLE 9.10: Examples of Clinical Trials involving MSC-Derived Exosomes 102](#_Toc61012487)

[TABLE 9.11: NIH Funding for Research on MSCs, 2020 103](#_Toc61012488)

[TABLE 9.11: (CONTINUED) 104](#_Toc61012489)

[TABLE 9.12: CIRM-Funded MSC Projects 105](#_Toc61012490)

[TABLE 9.13: MSC-Based Clinical Trials Funded by CIRM 106](#_Toc61012491)

[TABLE 10.1: Examples of Bioengineered MSCs Loaded with Therapeutics 110](#_Toc61012492)

[TABLE 10.2: Examples of Bioengineered MSCs used as Anti-Cancer Trojan Horses 111](#_Toc61012493)

[TABLE 11.1: Select Cases of Modified MSC Applications and Therapeutic Outcome 121](#_Toc61012494)

[TABLE 12.1: Select MSC-Based Clinical Trials for Autoimmune Diseases 123](#_Toc61012495)

[TABLE 12.2: Select MSC-Based Clinical Trials for Cardiovascular Diseases 124](#_Toc61012496)

[TABLE 12.3: Select MSC-Based Clinical Trials for Neurodegenerative Diseases 125](#_Toc61012497)

[TABLE 12.4: Select MSC-Based Clinical Trials for Bone and Cartilage Diseases 126](#_Toc61012498)

[TABLE 13.1: Examples of Completed Clinical Trials involving MSCs 129](#_Toc61012499)

[TABLE 13.2: MSC Products with Marketing Approval 130](#_Toc61012500)

[TABLE 13.3: Marketed Products Containing MSCs in Matrices 135](#_Toc61012501)

[TABLE 13.4: Disease Conditions Studied using Stem Cell Conditioned Medium (CM) 145](#_Toc61012502)

[TABLE 13.5: List of Stem Cell-Based Cosmetics 146](#_Toc61012503)

[TABLE 13.5: (CONTINUED) 147](#_Toc61012504)

[TABLE 13.5: (CONTINUED) 148](#_Toc61012505)

[TABLE 13.5: (CONTINUED) 149](#_Toc61012506)

[TABLE 13.5: (CONTINUED) 150](#_Toc61012507)

[TABLE 13.5: (CONTINUED) 151](#_Toc61012508)

[TABLE 13.5: (CONTINUED) 152](#_Toc61012509)

[TABLE 14.1: Price Tags of MSC-Based Approved CT Products 155](#_Toc61012510)

[TABLE 14.2: Price Tags for Select MSC Progenitor-Based Products 156](#_Toc61012511)

[TABLE 14.3: Global Market for MSC-Based Cell Therapy by Geography, 2020-2027 158](#_Toc61012512)

[TABLE 14.4: Global Market for Mesenchymal Stem Cells by Geography, 2020-2027 161](#_Toc61012513)

[TABLE 15.1: Alexerion’s Exosome-Based Pipeline 169](#_Toc61012514)

[TABLE 15.2: BrainStorm’s Product Pipeline 190](#_Toc61012515)

[TABLE 15.3: Celltex Therapeutics’ Clinical Trials 195](#_Toc61012516)

[TABLE 15.4: The Cellgram Pipeline from Pharmicell 239](#_Toc61012517)

[TABLE 15.5: Pluristem’s Clinical Pipeline 242](#_Toc61012518)

[TABLE 15.6: Sentien’s Pipeline 253](#_Toc61012519)

[TABLE 15.7: Stemedica’s Clinical Pipeline 256](#_Toc61012520)

About BioInformant:

**As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine.**

**Serving Fortune 500 companies that include Pfizer, GE Healthcare, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.**

**To learn more, visit BioInformant.com.**

**BioInformant Worldwide, LLC**

**www.BioInformant.com**